A Phase 3 randomized, controll tria...
A Phase 3 randomized, controll trial demonstrated that the breast cancer medicine Femara (letrozole, Novartis Oncology, East Hanover, NJ) is a more effective therapy than tamoxifen for postmenopausal women with hormone receptor positive tumors. In the trial, 324 women were administered the
|